Clinical Trial Update: Immunogenicity and Safety of Co-immunization With Cecolin and Hecolin [Phase 4]

View source ↗

Summary

Phase 4 trial investigating immunogenicity and safety of co-immunization with Cecolin and Hecolin for HPV-16/18 infections and Hepatitis E Virus infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis E
• Human Papillomavirus 16 Infection
• Human Papillomavirus 18 Infection

Drugs mentioned

• Cecolin (HPV-16/18 bivalent vaccine)
• Hecolin (HEV-239 recombinant vaccine)

Snippet

Sponsor: Xiamen Innovax Biotech Co., Ltd | Conditions: Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18 | Phase 4 | Status: UNKNOWN